Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

AMR is increasingly being recognized as an important cause of renal allograft injury, contributing to significant morbidity and graft loss. There are few controlled trials and no well-established treatment guidelines for AMR in renal transplant recipients. We retrospectively reviewed the outcome of four pediatric renal transplant recipients on a steroid minimization immunosuppression protocol treated with bortezomib for elevated DSA and acute AMR from 2012 to 2013. All patients received four doses of bortezomib 1.3 mg/m2 given on days one, four, eight, and 11. All patients also received other treatments prior to bortezomib, which may have included rituximab, methylprednisolone, plasmapheresis, and/or IVIg. While bortezomib in addition to other therapies significantly decreased DSA titers, DSA remained very elevated months after treatment. All four patients had immediate improvement or stabilization of renal function but one eventually lost her graft. There were no adverse events related to bortezomib six months after treatment.

Original languageEnglish (US)
Pages (from-to)463-468
Number of pages6
JournalPediatric Transplantation
Volume18
Issue number5
DOIs
StatePublished - 2014

Keywords

  • adolescent
  • antibody-mediated rejection
  • bortezomib
  • children
  • kidney transplantation

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation
  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen'. Together they form a unique fingerprint.

Cite this